Clinic Roundup

• Neurelis Inc., of San Diego, said the FDA cleared the investigational new drug application for NRL-1, an intranasal diazepam formulation, to begin clinical trials in acute breakthrough seizures. Delivered through a commercially available nasal sprayer, NRL-1 is being developed to manage patients who require intermittent use of diazepam to control bouts of acute repetitive seizure activity outside the hospital setting.